Have a feature idea you'd love to see implemented?
Let us know!
CARM Carisma Therapeutics Inc
Price (delayed)
$0.8478
Market cap
$35.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.52
Enterprise value
$11.83M
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is
Highlights
The company's EPS has surged by 86% YoY and by 13% QoQ
The net income rose by 23% year-on-year and by 12% since the previous quarter
The company's revenue rose by 41% YoY but it fell by 2.1% QoQ
CARM's gross profit is up by 41% year-on-year but it is down by 2.1% since the previous quarter
The equity has shrunk by 124% YoY
Carisma Therapeutics's quick ratio has plunged by 65% YoY
Key stats
What are the main financial stats of CARM
Market
Valuations
Earnings
Shares outstanding
41.75M
Market cap
$35.4M
Enterprise value
$11.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.58
Revenue
$20.27M
EBIT
-$66.33M
EBITDA
-$55.99M
Free cash flow
-$68.35M
Per share
Balance sheet
Liquidity
EPS
-$1.52
Free cash flow per share
-$1.64
Book value per share
-$0.27
Revenue per share
$0.49
TBVPS
$1.01
Total assets
$42.06M
Total liabilities
$53.18M
Debt
$3.32M
Equity
-$11.13M
Working capital
$23.58M
Debt to equity
-0.3
Current ratio
3.23
Quick ratio
2.55
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-276.3%
Gross margin
100%
Net margin
-314.8%
Operating margin
-329.5%
Return on assets
-96.4%
Return on equity
-957.2%
Return on invested capital
-1,026.4%
Return on capital employed
-210.6%
Return on sales
-327.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARM stock price
How has the Carisma Therapeutics stock price performed over time
Intraday
-1.69%
1 week
-9.7%
1 month
-13.27%
1 year
-65.25%
YTD
-71.06%
QTD
-13.63%
Financial performance
How have Carisma Therapeutics's revenue and profit performed over time
Revenue
$20.27M
Gross profit
$20.27M
Operating income
-$66.77M
Net income
-$63.8M
Gross margin
100%
Net margin
-314.8%
The net margin has grown by 45% YoY and by 10% from the previous quarter
The operating margin is up by 42% year-on-year and by 10% since the previous quarter
The company's revenue rose by 41% YoY but it fell by 2.1% QoQ
CARM's gross profit is up by 41% year-on-year but it is down by 2.1% since the previous quarter
Growth
What is Carisma Therapeutics's growth rate over time
Valuation
What is Carisma Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.58
The company's EPS has surged by 86% YoY and by 13% QoQ
The equity has shrunk by 124% YoY
The price to sales (P/S) is 85% lower than the 5-year quarterly average of 11.5 and 61% lower than the last 4 quarters average of 4.5
The company's revenue rose by 41% YoY but it fell by 2.1% QoQ
Efficiency
How efficient is Carisma Therapeutics business performance
The return on equity has dropped by 178% since the previous quarter and by 22% year-on-year
The company's return on sales rose by 42% YoY and by 10% QoQ
CARM's ROA is down by 37% year-on-year and by 10% since the previous quarter
The return on invested capital has declined by 7% since the previous quarter
Dividends
What is CARM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARM.
Financial health
How did Carisma Therapeutics financials performed over time
Carisma Therapeutics's total assets is 21% lower than its total liabilities
Carisma Therapeutics's quick ratio has plunged by 65% YoY
Carisma Therapeutics's total assets has shrunk by 61% YoY and by 29% QoQ
The debt is 130% more than the equity
The equity has shrunk by 124% YoY
CARM's debt to equity has shrunk by 103% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.